Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML

Hagop Kantarjian; Francis Giles; Susan O'Brien; Jorge E Cortes; Oliver G. Ottmann; Lydia Wunderle; Barbara Wassmann; Dieter Hoelzer; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Margaret Dugan; Leila Alland; Andreas Hochhaus; Kapil Bhalla; Maher Albitar; James D. Griffin

Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML

Hagop Kantarjian
, Francis Giles
, Susan O'Brien
, Jorge E Cortes
, Oliver G. Ottmann
, Lydia Wunderle
, Barbara Wassmann
, Dieter Hoelzer
, Chiaki Tanaka
, Paul Manley
, Patricia Rae
, William Mietlowski
, Kathy Bochinski
, Margaret Dugan
, Leila Alland
, Andreas Hochhaus
, Kapil Bhalla
, Maher Albitar
, James D. Griffin

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	711
Number of pages	1
Journal	Cancer Biology and Therapy
Volume	5
Issue number	7
State	Published - Jul 2006

ASJC Scopus subject areas

Molecular Medicine
Oncology
Pharmacology
Cancer Research

Cite this

Kantarjian, H., Giles, F., O'Brien, S., Cortes, J. E., Ottmann, O. G., Wunderle, L., Wassmann, B., Hoelzer, D., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Dugan, M., Alland, L., Hochhaus, A., Bhalla, K., Albitar, M., & Griffin, J. D. (2006). Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML. Cancer Biology and Therapy, 5(7), 711.

Kantarjian, H, Giles, F, O'Brien, S, Cortes, JE, Ottmann, OG, Wunderle, L, Wassmann, B, Hoelzer, D, Tanaka, C, Manley, P, Rae, P, Mietlowski, W, Bochinski, K, Dugan, M, Alland, L, Hochhaus, A, Bhalla, K, Albitar, M & Griffin, JD 2006, 'Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML', Cancer Biology and Therapy, vol. 5, no. 7, pp. 711.

@article{d7cc3ede366340f198c44a3af4cc83a5,

title = "Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML",

author = "Hagop Kantarjian and Francis Giles and Susan O'Brien and Cortes, \{Jorge E\} and Ottmann, \{Oliver G.\} and Lydia Wunderle and Barbara Wassmann and Dieter Hoelzer and Chiaki Tanaka and Paul Manley and Patricia Rae and William Mietlowski and Kathy Bochinski and Margaret Dugan and Leila Alland and Andreas Hochhaus and Kapil Bhalla and Maher Albitar and Griffin, \{James D.\}",

year = "2006",

month = jul,

language = "English (US)",

volume = "5",

pages = "711",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML

AU - Kantarjian, Hagop

AU - Giles, Francis

AU - O'Brien, Susan

AU - Cortes, Jorge E

AU - Ottmann, Oliver G.

AU - Wunderle, Lydia

AU - Wassmann, Barbara

AU - Hoelzer, Dieter

AU - Tanaka, Chiaki

AU - Manley, Paul

AU - Rae, Patricia

AU - Mietlowski, William

AU - Bochinski, Kathy

AU - Dugan, Margaret

AU - Alland, Leila

AU - Hochhaus, Andreas

AU - Bhalla, Kapil

AU - Albitar, Maher

AU - Griffin, James D.

PY - 2006/7

Y1 - 2006/7

UR - https://www.scopus.com/pages/publications/33751187562

UR - https://www.scopus.com/pages/publications/33751187562#tab=citedBy

M3 - Comment/debate

AN - SCOPUS:33751187562

SN - 1538-4047

VL - 5

SP - 711

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 7

ER -

Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML

ASJC Scopus subject areas

Other files and links

Cite this